LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Improved Stem Cell Technology Enables Mass Differentiation of Muscle Fiber Cells

By LabMedica International staff writers
Posted on 16 Aug 2015
Image: Micrograph of differentiated muscle fibers (green) with cell nuclei shown in blue (Photo courtesy of Dr. Olivier Pourquié, Harvard University Medical School).
Image: Micrograph of differentiated muscle fibers (green) with cell nuclei shown in blue (Photo courtesy of Dr. Olivier Pourquié, Harvard University Medical School).
Improvements in stem cell technology have enabled the in vitro differentiation and growth of large numbers of muscle fiber cells, including muscle fibers from a mouse model of Duchenne muscular dystrophy.

During embryonic development, skeletal muscles arise from somites, which derive from the presomitic mesoderm (PSM). Using PSM development as a guide, investigators at Harvard University Medical School (Boston, MA, USA) were able to establish conditions for the differentiation of monolayer cultures of mouse embryonic stem (ES) cells into PSM-like cells without the introduction of transgenes or cell sorting.

The investigators showed that development of primary and secondary skeletal muscle could be recapitulated in vitro from the PSM-like cells, providing an efficient, serum-free protocol for the generation of striated, contractile fibers from mouse and human pluripotent cells.

Results published in the August 3, 2015, online edition of the journal Nature Biotechnology further revealed that mouse ES cells also differentiated into Pax7+ cells with satellite cell characteristics, including the ability to form dystrophin+ fibers when grafted into muscles of dystrophin-deficient mdx mice, a model of Duchenne muscular dystrophy (DMD). Fibers derived from ES cells of mdx mice exhibited an abnormal branched phenotype resembling that described in vivo, thus providing an attractive model to study the origin of the pathological defects associated with DMD.

“This has been the missing piece: the ability to produce muscle cells in the lab could give us the ability to test out new treatments and tackle a spectrum of muscle diseases,” said senior author Dr. Olivier Pourquie, professor of genetics at Harvard University Medical School. “We took the hard route: we wanted to recapitulate all of the early stages of muscle cell development that happen in the body and re-create that in a dish in the lab. We analyzed each stage of early development, and generated cell lines that glowed green when they reached each stage. Going step by step, we managed to mimic each stage of development and coax cells toward muscle cell fate.”

Related Links:

Harvard University Medical School


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more